Announcements
- Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
- Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
- Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024
- Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
- Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
- Vivoryon Therapeutics N.V. Announces Changes to Board Composition
- Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
- Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
- Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
- Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 26.07m |
Free float | 17.35m |
P/E (TTM) | -- |
Market cap | 62.43m EUR |
EPS (TTM) | -1.13 EUR |
Data delayed at least 15 minutes.
More ▼